The uptake of 68Ga-PSMA on PET/CT in patients with prostate cancer with Gleason score of ≥8 or PSA level of ≥10ng/mL was significantly higher than those in patients with prostate cancer with Gleason score of <8 or PSA level <10 (5–18), and similar results were presented in a meta-analysis study conducted by Afshar-Oromieh et al. (29) on the prediction of 68Ga-PSMA PET/CT for prostate cancer recurrence. The gene discussed is FOLH1; the disease is prostate cancer.